Dexcom (DXCM) Cash from Financing Activities (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash from Financing Activities data on file, last reported at -$25.0 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 300.0% year-over-year to -$25.0 million in Q1 2026; TTM through Mar 2026 was -$1.7 billion, a 137.13% decrease from a year earlier, with the FY2025 full-year figure at -$1.7 billion, down 129.5% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$25.0 million, up from -$1.5 billion in the prior quarter.
• Over the last five years, Cash from Financing Activities for DXCM reached as high as $939.5 million in Q2 2023 and fell as low as -$1.5 billion in Q4 2025.
• Historically, Cash from Financing Activities has averaged -$195.1 million across 5 years, with a median of -$1.7 million in 2025.
• Across the five-year window, Cash from Financing Activities jumped 21948.84% in 2023 and plunged 95037.5% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$1.0 million in 2022, then plunged by 63090.0% to -$631.9 million in 2023, then soared by 99.75% to -$1.6 million in 2024, then plunged by 95037.5% to -$1.5 billion in 2025, then surged by 98.36% to -$25.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$25.0 million in Q1 2026, -$1.5 billion in Q4 2025, and -$175.0 million in Q3 2025.